MDGL Madrigal Pharmaceuticals, Inc.
High-Growth Software
F 28.4 / 100 pillar composite

AlphaQuality composite grade, weighted for high-growth software businesses.

⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.

Grade overrides the 28.4 pillar composite — hard gates always win.

Profitability

Weight: 15%
F 16
  • 5yr Avg ROIC -26.6%
  • Operating Margin Trend +0.00 pp/yr

Capital Efficiency

Weight: 15%
F 0
  • 5yr Avg ROE -55.3%
  • 5yr Share-Count CAGR 7.9%

Growth Quality

Weight: 35%
C 56
  • 5yr Revenue CAGR 432.1%
  • 5yr EPS CAGR 0.0%
  • Revenue-Growth Years (5) 1/5

Cash Generation

Weight: 20%
F 0
  • 5yr FCF Margin -136.8%
  • 5yr FCF/NI Conversion 0.00x

Balance Sheet

Weight: 10%
F 25
  • Net Debt / EBITDA 10.00x
  • Interest Coverage (EBIT/Int) -11.92x
  • Altman Z-Score 8.87

Stability

Weight: 5%
B+ 77
  • EPS Volatility (σ/μ) 0.00
  • Piotroski F-Score 2
  • Negative-Revenue Years (5) 0/5

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Trimming

3 of 3 gurus held; 3 trimmed.

Holders
3
Avg Δ position
-39.4%
New buys
0
Full exits
0
As of Q1 2026